# Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

> **NCT03601507** · PHASE2 · TERMINATED · sponsor: **University of Arizona** · enrollment: 9 (actual)

## Conditions studied

- CDKN2A-p16 Positive
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7
- Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7
- Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7

## Interventions

- **DRUG:** Alpelisib
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacodynamic Study
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT03601507
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-11
- **Primary completion:** 2022-05-24
- **Final completion:** 2022-05-24
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Novartis has chosen to withdraw support for this trial
- **Last updated:** 2024-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03601507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03601507, "Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03601507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*